ABSTRACT
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death. Developing minimally invasive techniques that can diagnose NSCLC, particularly at an early stage, may improve its outcome. Using microarray platforms, we previously identified 12 microRNAs (miRNAs) the aberrant expressions of which in primary lung tumors are associated with early-stage NSCLC. Here, we extend our previous research by investigating whether the miRNAs could be used as potential plasma biomarkers for NSCLC. We initially validated expressions of the miRNAs in paired lung tumor tissues and plasma specimens from 28 stage I NSCLC patients by real-time quantitative reverse transcription PCR, and then evaluated diagnostic value of the plasma miRNAs in a cohort of 58 NSCLC patients and 29 healthy individuals. The altered miRNA expressions were reproducibly confirmed in the tumor tissues. The miRNAs were stably present and reliably measurable in plasma. Of the 12 miRNAs, five displayed significant concordance of the expression levels in plasma and the corresponding tumor tissues (all r>0.850, all P<0.05). A logistic regression model with the best prediction was defined on the basis of the four genes (miRNA-21, -126, -210, and 486-5p), yielding 86.22% sensitivity and 96.55% specificity in distinguishing NSCLC patients from the healthy controls. Furthermore, the panel of miRNAs produced 73.33% sensitivity and 96.55% specificity in identifying stage I NSCLC patients. In addition, the genes have higher sensitivity (91.67%) in diagnosis of lung adenocarcinomas compared with squamous cell carcinomas (82.35%) (P<0.05). Altered expressions of the miRNAs in plasma would provide potential blood-based biomarkers for NSCLC.
Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Non-Small-Cell Lung/diagnosis , Lung Neoplasms/blood , Lung Neoplasms/diagnosis , MicroRNAs/blood , Adenocarcinoma/diagnosis , Adenocarcinoma of Lung , Aged , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Squamous Cell/diagnosis , Female , Humans , Logistic Models , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and SpecificityABSTRACT
Objective To explore the effects of deoxynivalenol (DON) on apoptosis of human gastric carcinoma cell line SNU in vitro. Methods SNU cells were treated with DON at different concentrations (50, 100, 1000, 2000 μg/L) for 12 hours, and then cells were harvested for cell apoptosis by flow cytometric (FCM) DNA analysis and the expression of Bax, Bcl-2 and Caspase-3 at protein level with FCM and Western blotting. Results FCM results showed that the apoptosis rates of SNU cells in DON treatment groups were all higher than that in control, especially in DON 1000 μg/L and 2000 μg/L groups (P<0.05). In the concentration range from 50 to 2000 μg/L, a significant concentration-depended response correlation could be found between apoptosis rate and DON concentration (r =0.940, P <0.01). FCM and Western blotting showed Bax and Caspase-3 expression in often SNU cells DON treatment for 12 hours were up-regulated while that of Bcl-2 was down-regulated. Conclusion DON can induce apoptosis of SNU cells in vitro in dose-dependent manner, and possible mechanisms of apoptosis induction effects may be up-regulation of the expression of Bax and down-regulation of that of Bcl-2 and activation of the key enzyme of apoptosis Caspase-3.
ABSTRACT
0.05). Conclusions:Compared with normal esophageal mucosa, the expression of HSP27 mRNA in esophageal squamous carcinoma and mucosa with atypical hyperplasia was markedly decreased.This indicated that the expression of HSP27 mRNA to a greater or less extent lost in the carcinogenesis and development of esophageal squamous carcinoma. To up-regulate the expression of HSP27 mRNA in esophageal squamous carcinoma may be a very effective biological therapy.
ABSTRACT
AIM: To explore the effects of sterigmatocystin (ST) on IL-4 expression and secretion of murine spleen cells in vitro. METHODS: The secretion and expression of IL-4 in murine spleen cells were studied with ELISA and semi-quantitative RT-PCR method after ST pretreatment at five different dosages (0.125 mg/L, 0.25 mg/L, 0.5 mg/L, 1 mg/L, 2 mg/L) for 2 h and 12 h, respectively. RESULTS: Semi-quantitative RT-PCR analysis showed that the expression of IL-4 mRNA in ST 0.125, 0.25 and 0.5 mg/L treated groups were higher than that in control group, especially in ST 0.5 mg/L group ( P
ABSTRACT
AIM: To explore the effects of sterigmatocystin (ST) on IL-2 and IFN-? expression and secretion in murine spleen cells in vitro. METHODS: The secretion and expression of IL-2 and IFN-? in murine spleen cells after ST pretreatment at five different dosages (0.125 mg/L, 0.25 mg/L, 0.5mg/L, 1mg/L, 2mg/L) were studied with ELISA and semi-quantitative RT-PCR method, respectively. RESULTS: Pretreatment of murine spleen cells in vitro with ST at five different dosages affected the IL-2 and IFN-? secretion at protein level and expression at mRNA level of the treated cells. The effects varied dependently to the ST dosage. At relatively lower dosages, ST induced the expression of IL-2 and IFN-? in murine spleen cells, while at relatively higher dosages, inhibitory effects were found, with the most significant inhibitory effects seen in ST 1 mg/L group. CONCLUSION: ST affected the secretion and expression of IL-2 and IFN-? in treated murine spleen cells. At relatively lower dosage, ST induced IL-2 and IFN-? secretion and expression, while at relatively higher dosages, inhibitory effects appeared.
